Difference between revisions of "Fluvoxamine-tranylcypromine"
From Psychiatrienet
(Created page with '{{Drugswitch | from = fluvoxamine | to = tranylcypromine | stop = * '''Before day 1:''' gradually reduce dosage of fluvoxamine to a maximum of 50 mg/day, when this dosage is ...') |
(No difference)
|
Revision as of 21:20, 3 May 2009
| ||||||||||||||||||||||
| ||||||||||||||||||||||
Switch medication from fluvoxamine to tranylcypromine.[1] [2]
Stop fluvoxamine - Before day 1: gradually reduce dosage of fluvoxamine to a maximum of 50 mg/day, when this dosage is > 50 mg/day.
- Day 1: reduce dosage of fluvoxamine further to 25 mg/day.
- Day 8: stop administration of fluvoxamine.
Start tranylcypromine- Day 8-13: a wash-out period of one week is necessary.
- Day 14: start tranylcypromine the next day in a normal dosage of 20 mg/day.
More information- A switch from fluvoxamine to tranylcypromine is not obvious, given the necessary prolonged wash-out period in this case.
- Occurrence of serotonin syndrome is reported when a wash-out period (of one week) is not considered.
- ↑ Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
- ↑ Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.
